SCHEMBL6965712

SCHEMBL6965712

COC(=O)c1ccc(OC(F)(C(=O)Cc2ccc(N(C(N)=O)c3ccccc3Br)cc2)N2CCCC2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 3/20 0.33
AR P10275 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
TNF P01375 1/20 0.32
NOD2 Q9HC29 1/20 0.32
NOD1 Q9Y239 1/20 0.32
KDM4E B2RXH2 2/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
NOTUM Q6P988 1/20 0.31
HRH1 P35367 1/20 0.31
NPC1 O15118 3/20 0.31
RAB9A P51151 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
MAPT P10636 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
POLB P06746 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6960242 0.90 MEN1 (0.38) CCR5ARSIRT1HDAC1HDAC6
SCHEMBL6953536 0.88 GAA (0.34) NPC1POLBGAA
SCHEMBL6968685 0.80 LMNA (0.36) RAB9APOLBGAAHPGDMEN1
SCHEMBL5149795 0.80 KDM4E (0.39) KDM4EMRGPRX4NPC1RAB9ASMN1; SMN2
SCHEMBL5150238 0.79 P2RY1 (0.46) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL5155307 0.77 NPC1 (0.47) TNFNOD2NOD1KDM4ENPC1
SCHEMBL5156530 0.75 ITGA4 (0.51) NPC1RAB9AMAPTPOLBGAA
SCHEMBL5155113 0.73 RAB9A (0.45) TNFNOD2NOD1KDM4ENPC1
SCHEMBL5149635 0.73 MAPT (0.56) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL5151831 0.73 P2RY1 (0.47) KDM4ENPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 CCR5 463/4885AR 1185/4885SIRT1 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.